AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
reserpine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| derivatives of Rauwolfia alkaloids | 2370 | 50-55-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.50 | mg | O |
| 0.50 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.14 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.606 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.966 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 36.813 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 31.842 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 2.120 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 7.490 | % | High | 1 |
| herg | hERG pIC50 | 5.155 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 60.117 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 136.773 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 2.240 | % | High | 1 |
| kinase-safety-class | ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIM2,PRKDC,STK33,TEK,TGFBR1,ZAP70 | 36 | |||
| kinase-selectivity-class | AXL,GRK2 | 2 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.309 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 154.882 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 2.960 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 5.534 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 6.090 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 189.234 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 19.930 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 2.060 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 3.221 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 12, 1955 | FDA | LANNETT |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C02AA02 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, CENTRALLY ACTING Rauwolfia alkaloids |
| ATC | C02AA52 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, CENTRALLY ACTING Rauwolfia alkaloids |
| ATC | C02LA01 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Rauwolfia alkaloids and diuretics in combination |
| ATC | C02LA51 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Rauwolfia alkaloids and diuretics in combination |
| ATC | C02LA71 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Rauwolfia alkaloids and diuretics in combination |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D014179 | Neurotransmitter Uptake Inhibitors |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D018759 | Adrenergic Uptake Inhibitors |
| MeSH PA | D049990 | Membrane Transport Modulators |
| FDA EPC | N0000175640 | Catecholamine-depleting Sympatholytic |
| FDA PE | N0000175650 | Decreased Sympathetic Activity |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35640 | adrenergic uptake inhibitor |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:35703 | xenobiotic |
| CHEBI has role | CHEBI:65190 | first generation antipsychotic |
| CHEBI has role | CHEBI:76779 | EC 3.4.21.26 (prolyl oligopeptidase) inhibitor |
| CHEBI has role | CHEBI:76924 | plant metabolite |
| CHEBI has role | CHEBI:78298 | environmental contaminant |
| CHEBI has role | CHEBI:145947 | antiatherosclerotic agent |
Related Drugs by ATC class:
C02AA Rauwolfia alkaloids 4 drugs
C02LA Rauwolfia alkaloids and diuretics in combination 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypertensive disorder | indication | 38341003 | DOID:10763 |
| Psychotic disorder | indication | 69322001 | |
| Fluid volume disorder | contraindication | 1860003 | |
| Anuria | contraindication | 2472002 | DOID:2983 |
| Suicidal thoughts | contraindication | 6471006 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Hypercholesterolemia | contraindication | 13644009 | |
| Chronic disease of respiratory system | contraindication | 17097001 | |
| Cirrhosis of liver | contraindication | 19943007 | DOID:5082 |
| Secondary angle-closure glaucoma | contraindication | 21571006 | |
| Electroconvulsive therapy | contraindication | 23835007 | |
| Hypovolemia | contraindication | 28560003 | |
| Dehydration | contraindication | 34095006 | |
| Depressive disorder | contraindication | 35489007 | |
| Hyperuricemia | contraindication | 35885006 | DOID:1920 |
| Hypokalemia | contraindication | 43339004 | |
| Diabetes mellitus type 2 | contraindication | 44054006 | DOID:9352 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Low blood pressure | contraindication | 45007003 | |
| Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
| Chronic heart failure | contraindication | 48447003 | |
| Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
| Sympathectomy | contraindication | 57071006 | |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
| Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
| Hypochloremic alkalosis | contraindication | 70134007 | |
| Hepatic coma | contraindication | 72836002 | DOID:12550 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Oliguria | contraindication | 83128009 | |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Hyponatremia | contraindication | 89627008 | |
| Gout | contraindication | 90560007 | DOID:13189 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Hypomagnesemia | contraindication | 190855004 | |
| Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
| Impaired renal function disorder | contraindication | 197663003 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Lupus erythematosus and erythema multiforme-like syndrome | contraindication | 238926009 | |
| Calculus in biliary tract | contraindication | 266474003 | |
| Neonatal hyperbilirubinemia | contraindication | 281610001 | |
| Hypertriglyceridemia | contraindication | 302870006 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Myocardial infarction in recovery phase | contraindication | 418044006 | |
| Slow acetylator due to N-acetyltransferase enzyme variant | contraindication | 425079005 | |
| Azotemia | contraindication | 445009001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.2 | acidic |
| pKa2 | 6.78 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Synaptic vesicular amine transporter | Transporter | INHIBITOR | Ki | 7.90 | IUPHAR | CHEMBL | |||
| D(2) dopamine receptor | GPCR | Ki | 6.23 | WOMBAT-PK | |||||
| Mu-type opioid receptor | GPCR | Ki | 5.77 | DRUG MATRIX | |||||
| Multidrug resistance protein 1 | Transporter | Ki | 7 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.74 | PDSP | |||||
| D(3) dopamine receptor | GPCR | Ki | 6.22 | WOMBAT-PK | |||||
| ATP-binding cassette sub-family G member 2 | Transporter | IC50 | 4.58 | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | IC50 | 5.77 | CHEMBL | |||||
| Cholinesterase | Enzyme | IC50 | 5.55 | CHEMBL | |||||
| Chromaffin granule amine transporter | Transporter | INHIBITOR | Ki | 7.45 | IUPHAR | ||||
| Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 5.80 | CHEMBL | |||||
| D(1A) dopamine receptor | GPCR | Ki | 5.42 | PDSP | |||||
| Sodium-dependent serotonin transporter | Transporter | Kd | 5.84 | SCIENTIFIC LITERATURE | |||||
| Synaptic vesicular amine transporter | Transporter | Ki | 9 | CHEMBL | |||||
| Quinolone resistance protein NorA | Transporter | IC50 | 5.15 | CHEMBL | |||||
| Synaptic vesicular amine transporter | Transporter | IC50 | 8.75 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017506 | VUID |
| N0000145891 | NUI |
| D00197 | KEGG_DRUG |
| 4017506 | VANDF |
| C0035179 | UMLSCUI |
| CHEBI:28487 | CHEBI |
| YHR | PDB_CHEM_ID |
| CHEMBL772 | ChEMBL_ID |
| D012110 | MESH_DESCRIPTOR_UI |
| DB00206 | DRUGBANK_ID |
| 4823 | IUPHAR_LIGAND_ID |
| 282 | INN_ID |
| 8B1QWR724A | UNII |
| 5770 | PUBCHEM_CID |
| 9260 | RXNORM |
| 1013 | MMSL |
| 5417 | MMSL |
| d00367 | MMSL |
| 000640 | NDDF |
| 387447004 | SNOMEDCT_US |
| 78379001 | SNOMEDCT_US |
| 8B1QWR724A | INXIGHT DRUGS |
Pharmaceutical products:
None